UCB to Use Nodality Technology - Analyst Blog


UCB ( UCBJF ) along with Nodality Inc. agreed for a strategic collaboration under which they will utilize Nodality's proprietary Single Cell Network Profiling (SCNP) technology to develop several of UCB's compounds. The multi-year agreement will initially be focused on immunology disorders.

Further, on the basis of information generated using Nodality's technology, the agreement will give UCB the option to engage Nodality in developing companion diagnostics for UCB's compounds.

Under the terms of the agreement, Nodality will receive an upfront payment, R&D funding, and success-based payments on the achievement of all applicable development, regulatory and commercialization milestones. Nodality will also be eligible to receive royalties on future diagnostic sales.

We note that this is the second collaboration that UCB has entered into in less than a month. In early February, UCB and Japanese pharmaceutical company Astellas Pharma Inc. announced a collaboration to jointly develop and commercialize Cimzia (certolizumab pegol) for rheumatoid arthritis ( RA ) in Japan.

According to the agreement, UCB will manufacture and supply Cimzia to Astellas for commercialization. Astellas will exclusively distribute the drug and also book sales, while both Astellas and UCB will jointly develop and commercialize Cimzia in Japan. Under the agreement, UCB will receive an initial cash payment and is also eligible to receive clinical, regulatory and commercial milestones payments.

UCB and Astellas have filed Cimzia with the Japanese regulatory authority, seeking approval of the drug for the treatment of RA in patients who have responded insufficiently to current therapies.

Cimzia is currently marketed in the US and Europe for the treatment of adults with moderate-to-severely active RA. The drug is also marketed in the US for reducing signs and symptoms of Crohn's disease (CD).

We currently have a Zacks #3 Rank (short-term Hold rating) on the stock.

To read this article on Zacks.com click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: RA



More from Zacks.com:

Related Videos



Most Active by Volume

  • $73 ▲ 6.35%
  • $15.85 ▲ 0.76%
  • $113.10 ▲ 0.11%
  • $6.91 ▲ 8.82%
  • $24.59 ▲ 0.45%
  • $47.01 ▼ 0.36%
  • $3.66 ▲ 2.52%
  • $35.10 ▼ 0.54%
As of 1/26/2015, 04:06 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com